RNA expression results show that, while E7046 or E7777 alone elicited modest gene expression changes compared with vehicle control, E7046 + E7777 treatment strongly upregulated numerous genes involved in antigen presentation, adhesion, Th1 cell differentiation, activation of cytotoxic mechanisms, Cxcr3 and Ccr5 ligand chemokines, but also tumor and myeloid-produced factors and known T cell co-inhibitory receptors (Fig. 7, Supplementary Fig. S6). The gene discussed is CCR5; the disease is neoplasm.